Proteus Syndrome Review: Molecular, Clinical, and Pathologic Features
Overview
Authors
Affiliations
Proteus syndrome is caused by an activating AKT1 mutation (c.49G>A, p.Glu17Lys). Many variable features are possible in this mosaic disorder, including: (i) disproportionate, asymmetric, and distorting overgrowth; (ii) bone abnormalities different from those observed in other disorders; (iii) a characteristic cerebriform connective tissue nevus made up of highly collagenized connective tissue; (iv) epidermal nevi in early life, consisting of acanthosis and hyperkeratosis; (v) vascular malformations of the capillary, venous, or lymphatic types; (vi) dysregulated adipose tissue including lipomas, lipohypoplasia, fatty overgrowth, and localized fat deposits; (vii) other unusual features, including bullous lung alterations; specific neoplasms; a facial phenotype associated with intellectual disability and/or seizures, and/or brain malformations; and (viii) deep vein thrombosis, resulting in premature death. Concluding remarks address diagnostic criteria, natural history, management, psychosocial issues, and differential diagnosis.
Proteus Syndrome: Case Report and Updated Literature Review.
Klimeczek-Chrapusta M, Kachnic M, Chrapusta A Arch Plast Surg. 2024; 51(4):423-431.
PMID: 39034978 PMC: 11257735. DOI: 10.1055/a-2300-7002.
Proteus Syndrome: A Rare Congenital Disorder.
Khaladkar S, Jhala N, Krishnani K, Durgi E Cureus. 2024; 16(5):e60072.
PMID: 38860105 PMC: 11163185. DOI: 10.7759/cureus.60072.
Lin P, Sun Z, Davis G Am J Pathol. 2023; 194(4):574-598.
PMID: 37838010 PMC: 10988768. DOI: 10.1016/j.ajpath.2023.08.017.
[Genetics, diagnostics and clinical presentation of primary lymphoedema].
Hagerling R Dermatologie (Heidelb). 2023; 74(8):594-604.
PMID: 37402871 DOI: 10.1007/s00105-023-05183-w.
Structure-Based Profiling of Potential Phytomolecules with AKT1 a Key Cancer Drug Target.
Mirza Z, Karim S Molecules. 2023; 28(6).
PMID: 36985568 PMC: 10051420. DOI: 10.3390/molecules28062597.